title: Topical dorzolamide treatment of macular cysts in the enhanced S-cone syndrome patient.
abstract: OBJECTIVE
  The purpose of the study was to evaluate the efficacy of a topical form of a carbonic anhydrase inhibitor (dorzolamide) on the foveal function and thickness in the eye of a patient with enhanced S-cone syndrome (ESCS) associated with macular cysts.
  
  
  METHODS
  Twenty-eight-year-old Polish man with ESCS and macular cysts appearance in the right eye was treated 3 times daily with 2.0 % dorzolamide drops for the period time equal to 6 months. Monthly controls included: best corrected distance visual acuity (BCDVA-logMAR), foveal thickness (optical coherence tomography, OCT) and foveal function (multi-focal electroretinography, mfERG).
  
  
  RESULTS
  Before treatment, BCDVA in the right eye was equal to 0.26 logMAR, improved to 0.1 logMAR during the first 3 months and remained stable for the next 3 months. After 6 months, foveal thickness decreased (from 482 to 224 μm) and foveal function improved (the amplitude of P1-wave density increased from 34.8 to 107.3 nV/deg(2)) and was between the ranges of normal values. Implicit time of P1-wave remained prolonged.
  
  
  CONCLUSIONS
  The results of our short-term study suggest potential efficacy of topical dorzolamide treatment in ESCS patients with macular cysts.
authors.affiliation: Chair and Clinic of Ophthalmology, Pomeranian Medical University, Powstańców Wlkp. Street 72, 70-111 Szczecin, Poland. martakiszkielis@gmail.com
authors.forename: Marta
authors.initials: M
authors.lastname: Kiszkielis
authors.forename: Wojciech
authors.initials: W
authors.lastname: Lubiński
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Penkala
mesh_terms: D000287:Administration, Topical; D000328:Adult; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage; D003560:Cysts / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D004596:Electroretinography; D015785:Eye Diseases, Hereditary / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D009883:Ophthalmic Solutions; D012162:Retinal Degeneration / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D013449:Sulfonamides / Q000008:administration & dosage*; D013876:Thiophenes / Q000008:administration & dosage*; D041623:Tomography, Optical Coherence; D014786:Vision Disorders / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D014792:Visual Acuity
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D009883:Ophthalmic Solutions; D013449:Sulfonamides; D013876:Thiophenes; C062765:dorzolamide